Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2016 Oct;89(1066):20160251.
doi: 10.1259/bjr.20160251. Epub 2016 Aug 24.

Stereotactic body radiotherapy for oligoprogressive cancer

Patrick Cheung  1
Affiliations

Stereotactic body radiotherapy for oligoprogressive cancer

Patrick Cheung. Br J Radiol. 2016 Oct.

Abstract

Stereotactic body radiotherapy (SBRT) is a focused tumour treatment that produces high local control rates with low toxicity. Its use in metastatic cancer is evolving rapidly, with purported benefits in the oligometastatic setting and for better palliation of symptomatic disease. Another potential indication for SBRT is in the setting of oligoprogression, where there is progression of a solitary or a few tumours while all other tumours are responding or stable on a systemic therapy strategy. SBRT to the progressing "rogue" tumours may delay the need to start or change systemic therapy. This may have clinical benefits including improved progression-free/overall survival and quality of life for patients. This review will summarize the limited published data. More prospective clinical trials are urgently needed to better identify and quantify the potential clinical benefits.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Stereotactic body radiotherapy dose distribution for a pulmonary metastasis as seen on select axial, sagittal and coronal planes.
See this image and copyright information in PMC

References

    1. Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. . Palliative radiotherapy for bone metastases: an ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 2011; 79: 965–76. doi: 10.1016/j.ijrobp.2010.11.026 - DOI - PubMed
    1. Rodrigues G, Videtic GM, Sur R, Bezjak A, Bradley J, Hahn CA, et al. . Palliative thoracic radiotherapy in lung cancer: an American Society for Radiation Oncology evidence-based clinical practice guideline. Pract Radiat Oncol 2011; 1: 60–71. doi: 10.1016/j.prro.2011.01.005 - DOI - PMC - PubMed
    1. Tsao MN, Rades D, Wirth A, Lo SS, Danielson BL, Gaspar LE, et al. . Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2012; 2: 210–25. doi: 10.1016/j.prro.2011.12.004 - DOI - PMC - PubMed
    1. Sahgal A, Aoyama H, Kocher M, Neupane B, Collette S, Tago M, et al. . Phase 3 trials of stereotactic radiosurgery with or without whole-brain radiation therapy for 1 to 4 brain metastases: individual patient data meta-analysis. Int J Radiat Oncol Biol Phys 2015; 91: 710–7. doi: 10.1016/j.ijrobp.2014.10.024 - DOI - PubMed
    1. Soliman H, Das S, Larson DA, Sahgal A. Stereotactic radiosurgery (SRS) in the modern management of patients with brain metastases. Oncotarget 2016; 7: 12318–30. doi: 10.18632/oncotarget.7131 - DOI - PMC - PubMed